Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone

18Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: a)To determine serum Transforming Growth Factor-beta 1 (TGF-β1) levels in patients with type 2 diabetes who do not have diabetes related complications and in healthy controls, b) to evaluate the effects of metformin and rosiglitazone on TGF-β1 levels. DESIGN: In the washout period, 61 patients with Fasting Plasma Glucose levels (FPG) higher than 140 mg/dl, Postprandial Glucose (PPG) levels higher than 180 mg/dl and A1c levels exceeding 6.5% were treated with glimperide. After 4 weeks, 39 of these patients were randomised to receive either metformin or rosiglitazone for 12 weeks. Thirty healthy controls were also studied. RESULTS: There were no significant differences with regard to age, gender, body weight and BMI between patients and healthy controls. Type 2 diabetics had higher waist circumference, FPG, total cholesterol, LDL-cholesterol and triglyceride levels. Baseline TGF-β1 levels in diabetics were higher than in controls (29.84±7.04 ng/ml vs 11.37±4.06 ng/ml, p<0.001). Metformin or rosiglitazone did not significantly modify the TGF-β1 levels. In a multiple regression analysis FPG was the only variable that was significantly associated with plasma TGF-β1 levels. CONCLUSION: The elevated levels of TGF-β1 in subjects with type 2 diabetes possibly indicate a tendency for renal and endothelial damage in such patients. The association of TGF-β1 with FPG possibly links poor diabetic control to vascular damage, leading to diabetic complications. Lack of changes in the levels of TGF-β1 after therapy may reflect inadequate therapy duration.

Cite

CITATION STYLE

APA

Yener, S., Comlekci, A., Akinci, B., Akan, P., Demir, T., Bayraktar, F., & Yesil, S. (2008). Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones, 7(1), 70–76. https://doi.org/10.14310/horm.2002.1111039

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free